MPLT insider trading
HealthcareMapLight Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. MapLight Therapeutics, Inc. was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.
Company website: www.maplightrx.com
MPLT insider activity at a glance
FilingIQ tracks 185 insider transactions for MPLT in filings since Oct 28, 2025. The most recent transaction is dated Sep 16, 2026.
Across the full history, 6 open-market purchases
and 139 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on MPLT insider trades is 55.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest MPLT Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for MPLT?
- FilingIQ tracks 185 Form 4 insider transactions for MPLT (MapLight Therapeutics, Inc.), covering filings from Oct 28, 2025 onwards. 54 of those are dated within the last 90 days.
- Are MPLT insiders net buyers or net sellers?
- Across the full Form 4 history for MPLT, 6 transactions (3%) were open-market purchases and 139 (75%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does MPLT insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is MPLT in?
- MapLight Therapeutics, Inc. (MPLT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $785.18M.
Methodology & sources
Every MPLT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.